 CAMBRIDGE, England BOSTON--BUSINESS WIRE--Bicycle Therapeutics plc NASDAQ:BCYC, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide Bicycle technology, today announced that an article highlighting preclinical studies of Bicycles novel, fully synthetic Bicycle systemic immune cell agonists and tumor-targeted immune cell agonists TICAsTM was published in the Journal for ImmunoTherapy of Cancer JITC. The article, 